Malaria remains a major cause of morbidity and mortality in the tropics, with Plasmodium
falciparum responsible for the majority of the disease burden and P. vivax being the …

Following anti-malarial drug treatment asexual malaria parasite killing and clearance
appear to be first order processes. Damaged malaria parasites in circulating erythrocytes …

Approximately 40% of the world population live in areas with the risk of malaria. Each year,
300–500 million people suffer from acute malaria, and 0.5–2.5 million die from the disease …

The gravity of the threat posed by vivax malaria to public health has been poorly
appreciated. The widely held misperception of Plasmodium vivax as being relatively …

Mixed-species malaria infections are often not recognized or underestimated. In Asia,
surveys usually report that< 2% of infections are mixed, whereas therapeutic studies in vivax …

Malaria, a parasite vector-borne disease, is one of the greatest health threats in tropical
regions, despite the availability of malaria chemoprophylaxis. The emergence and rapid …

Clinical trials from the 1970s and 1980s have shown the efficacy, safety, and practicability of
the treatment of Plasmodium falciparum malaria with clindamycin. Two reviews from the …

Plasmodium vivax infections often recur due to relapse of hypnozoites from the liver. In
malaria-endemic areas, tools to distinguish relapse from reinfection are needed. We applied …

Malaria remains one of the world's most prevalent tropical diseases because of its high
mortality and morbidity burden, as well as its economic and social impacts on the …

Malaria incidence data at the district level from 1997 to 2002 and total malaria case data
from 1965 to 2002 in Thailand were analyzed to determine the spatial and temporal …